Synthetic studies towards the total synthesis of the neocarzinostatin chromophore

The chromoprotein Neocarzinostatin (NCS) was the first isolated member of the so- called 'enediyne' class of antibiotics and was found to exhibit broad-spectrum antitumor activity. NCS was isolated in 1965 from the bacterium Streptomyces carzinostaticus and is made up of a 1:1 non-covalent complex of an extraordinarily reactive nine-membered ring epoxydiyne chromophore (NCS-C) tightly bound to a protein known as apo-NCS. The antitumor activity arises solely from the chromophore which acts as a DNA-cleaving agent initiated by radical hydrogen abstraction of a deoxyribose residue. The apoprotein protects, carries and delivers the chromophore offering potential as a novel, more selective drug delivery system. Our general strategy towards NCS-C involves the Michael addition of an epoxydiyne to a cyclopentenone followed by cyclisation via an aldol reaction. The enantioselective synthesis of the cyclopentenone fragment had already been synthesised within the group via enzyme-mediated kinetic resolution. The aim of this project is to report our current efforts to establish a general method for the synthesis of epoxydiynes in order to apply our own Michael/aldol sequence. Different routes to these epoxydiynes have been developed using a Sharpless asymmetric epoxidation. However, these have proven to be extremely difficult due to the formation of unstable intermediates which could not be processed to fully elaborated epoxydiynes. After considerable investigation, a concise and convergent approach to epoxydiynes was finally achieved on a multi-gram scale. This involves a diastereoselective addition of an allenyl zinc bromide to propargylic ketones/aldehydes followed by epoxide formation. This new protocol enables us to synthesise fully functionalised and stereochemically pure epoxydiynes including C-8 provides a very simple synthetic route to other functionalised epoxydiynes. Owing to the flexibility of our new method, epoxydiynes with different protecting groups can now be readily prepared enabling us to screen them in new Michael addition reaction studies

Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation.

Administration of human pancreatic tumor growth hormone (GH) releasing factor (hpGRF[1-40]) as a single injection to normal human subjects stimulates the secretion of GH in a dose-responsive manner. In the present studies, hpGRF(1-40) was infused in a graded stepwise manner over a 6-h period in order to determine whether the GH secretory response would be sustained. Normal adult males received four consecutive 90-min infusions of hpGRF(1-40) at doses of 1, 3.3, 10, and 33 ng/kg per min, preceded and followed by a 90-min saline infusion; and the plasma GH responses were compared with those during a separate control infusion. Plasma GH levels were significantly elevated by each hpGRF(1-40) infusion; and dose responsiveness was evident for the lowest three doses. Mean integrated GH secretory rates for the four doses were 1.95, 3.29, 4.29, and 3.65 times those of the respective control study. Plasma GH responses exhibited considerable variability, frequently decreasing during the latter part of each infusion; and at the highest dose, they decreased continuously beginning shortly after the onset of infusion. Episodic GH secretion occurred in individual subjects during each of the infusion periods. The possible contribution of hypothalamic somatostatin secretion to the diminished GH responsiveness was evaluated by determining plasma thyroid stimulating hormone (TSH) levels during the infusions and the TSH responses to thyrotropin-releasing hormone (500 micrograms i.v.) during a separate hpGRF(1-40) infusion of 2 ng/kg per min. Neither basal nor stimulated TSH levels differed between GRF-infused and control groups. The results indicate that GH secretion is dose responsive to hpGRF(1-40) infusions, though the response to hpGRF(1-40) infusions, though the response is complex. The absence of impaired TSH secretion provides evidence against a mediating role of somatostatin. The explanation for the loss of GH responsiveness remains undetermined but could include GRF-induced receptor down-regulation, a postreceptor effect, or, in spite of our negative results, a somatostatin-mediated inhibition

Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man.

The metabolic clearance rate (MCR) and plasma disappearance rate (t1/2) of human pancreatic tumor growth hormone releasing factor [hpGRF(1-40)] was determined in normal adult male subjects by single injection and constant infusion techniques. Single injections of 1, 3.3, and 10 micrograms/kg hpGRF(1-40) were administered intravenously, plasma immunoreactive (IR) GRF levels were measured during the subsequent 180 min, and biexponential curve analysis was performed. Graded, dose-constant infusions of hpGRF(1-40) at rates of 1, 3.3, 10, and 33 ng/kg per min were administered and the MCR was calculated from measurement of steady state plasma IR-GRF levels at each infusion rate. The postinfusion disappearance rate was determined by linear regression analysis of plasma IR-GRF levels during the 120-min period after cessation of the infusion. The calculated MCR during the single injection study was 194 +/- 17.5 liters/m2 per d and was not significantly different from the calculated value during the constant infusion study (202 +/- 16 liters/m2 per d). The disappearance rate during the single injection study was subdivided into two linear phases: an initial equilibration phase (7.6 +/- 1.2 min) and a subsequent elimination phase (51.8 +/- 5.4 min). The latter was similar to the linear disappearance rate observed (41.3 +/- 3.0 min) after cessation of the constant infusion. The chromatographic and biologic characteristics of plasma IR-GRF, 30 min after injection, were similar to those of synthetic hpGRF(1-40). The results have been discussed in relation to the MCR of other hypothalamic hormones and have been used to extrapolate secretion rates of GRF in patients with ectopic GRF production

OMNY-A tOMography Nano crYo stage

For many scientific questions gaining three-dimensional insight into a specimen can provide valuable information. We here present an instrument called "tOMography Nano crYo (OMNY)," dedicated to high resolution 3D scanning x-ray microscopy at cryogenic conditions via hard X-ray ptychography. Ptychography is a lens-less imaging method requiring accurate sample positioning. In OMNY, this in achieved via dedicated laser interferometry and closed-loop position control reaching sub-10 nm positioning accuracy. Cryogenic sample conditions are maintained via conductive cooling. 90 K can be reached when using liquid nitrogen as coolant, and 10 K is possible with liquid helium. A cryogenic sample-change mechanism permits measurements of cryogenically fixed specimens. We compare images obtained with OMNY with older measurements performed using a nitrogen gas cryo-jet of stained, epoxy-embedded retina tissue and of frozen-hydrated Chlamydomonas cells. (C) 2018 Author(s)